Answers are grounded in this paper and cite their sources.
Ibrutinib was highly active, associated with durable responses, and safe in pretreated patients with Waldenström's macroglobulinemia. MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01614821.).
No takes yet. Share an insight, caveat, or question.
Treon et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: